Edgestream Partners L.P. boosted its holdings in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 218.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,301 shares of the company's stock after acquiring an additional 22,829 shares during the quarter. Edgestream Partners L.P.'s holdings in Henry Schein were worth $2,281,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Investment Management Corp VA ADV acquired a new stake in Henry Schein in the fourth quarter valued at $32,000. Rakuten Securities Inc. acquired a new stake in Henry Schein in the first quarter valued at $34,000. UMB Bank n.a. grew its holdings in Henry Schein by 23.2% in the first quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock valued at $73,000 after purchasing an additional 201 shares during the last quarter. Allworth Financial LP grew its holdings in Henry Schein by 24.5% in the first quarter. Allworth Financial LP now owns 1,178 shares of the company's stock valued at $78,000 after purchasing an additional 232 shares during the last quarter. Finally, Menard Financial Group LLC acquired a new stake in shares of Henry Schein during the fourth quarter valued at $92,000. Hedge funds and other institutional investors own 96.62% of the company's stock.
Analyst Ratings Changes
A number of research firms recently commented on HSIC. Piper Sandler decreased their price objective on Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. Leerink Partners set a $75.00 price objective on Henry Schein in a research note on Monday, July 14th. Robert W. Baird reaffirmed a "neutral" rating and set a $72.00 price objective (down previously from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Baird R W lowered Henry Schein from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 14th. Finally, Evercore ISI raised their price target on Henry Schein from $72.00 to $78.00 and gave the stock an "in-line" rating in a research note on Wednesday, July 9th. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Henry Schein presently has an average rating of "Hold" and an average price target of $78.36.
Check Out Our Latest Analysis on HSIC
Henry Schein Trading Down 0.6%
Shares of Henry Schein stock traded down $0.40 during trading hours on Friday, reaching $69.10. The stock had a trading volume of 1,177,871 shares, compared to its average volume of 1,742,763. The firm has a 50 day simple moving average of $71.81 and a two-hundred day simple moving average of $71.33. The firm has a market capitalization of $8.41 billion, a price-to-earnings ratio of 21.59, a P/E/G ratio of 2.23 and a beta of 0.87. The company has a current ratio of 1.38, a quick ratio of 0.75 and a debt-to-equity ratio of 0.50. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.11 by $0.04. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a return on equity of 14.87% and a net margin of 3.21%. The company's quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the business posted $1.10 EPS. As a group, equities research analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.
Henry Schein Company Profile
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also
Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
